Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts

J Allergy Clin Immunol Pract. Sep-Oct 2019;7(7):2151-2153. doi: 10.1016/j.jaip.2019.05.051. Epub 2019 Jun 13.

Abstract

Antibiotic allergies are reported in up to 1 in 4 immunocompromised hosts with significant impacts on antibiotic utilization and patient outcomes. Health services programs focused on de-labeling beta-lactam and sulfonamide allergy labels should be a standard of care in immunocompromised hosts.

Keywords: Antibiotic allergy; Antibiotic allergy testing; Penicillin allergy; Penicillin allergy testing.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / adverse effects*
  • Chemoprevention / methods
  • Drug Hypersensitivity / diagnosis*
  • Drug Hypersensitivity / etiology
  • Humans
  • Immunocompromised Host*
  • Penicillins / adverse effects
  • Self Report
  • Skin Tests
  • Sulfonamides / adverse effects*
  • Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects
  • beta-Lactams / adverse effects*

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Sulfonamides
  • beta-Lactams
  • Trimethoprim, Sulfamethoxazole Drug Combination